Please use this identifier to cite or link to this item: https://ah.lib.nccu.edu.tw/handle/140.119/49457
題名: 慢性B型肝炎病毒感染之年齡相關模型及存活機率分析
An age-dependent model with survival analysis on chronic hepatitis b virus infection
作者: 陳炘毓
Chen, Shin Yu
貢獻者: 陸行
Luh, Hsing
陳炘毓
Chen, Shin Yu
關鍵詞: 類馬可夫鏈
存活分析
B型肝炎
第一次到達時間
國民生命表
semi-Markov chain
Survival analysis
HBV
First passage time
Life table
日期: 2010
上傳時間: 8-Dec-2010
摘要: 在此篇論文中,我們提出一個慢性B型肝炎病毒感染病程之數學模型。因為在病症間的轉移機率(Transition probability)是隨著患者的年齡變動,所以在過去的文獻中,已經有學者提出,在疾病轉移機率模型中,應加入國民生命表(Life table),藉此讓機率模型更符合B型肝炎病患的生命歷程。但是過去的文獻中,學者並沒有利用加入國民生命表之後疾病模型做進一步的病程分析。在這篇論文當中,我們假設原始的疾病轉移模型是符合馬可夫鏈的性質,並且提出一種加入國民生命表的方法,賦予疾病有年齡相關特性之模型。根據文獻數據和類馬可夫機率性質,我們使用著名的Chapman-Kolmogorov公式計算B型肝炎的自然病程機率,並畫出病人的生存機率曲線(Survival curve)。文章最後將會藉由兩個例子來介紹此篇論文提出的模型。實驗數據結果證實,此模型不僅提供了一個更精確的方法去分析在病症與死亡間的轉移機率、平均餘命(Life expectancy)、以及在不同年齡的存活機率(Survival probability),並且可以更進一步的分析且瞭解病情狀態之間的轉移狀況。
In this thesis, we propose a new mathematical model extending the natural history of hepatitis B virus (HBV) prognosis progression on chronic HBV infection. Since the actual transition probabilities between symptoms are dependent of ages, it has been proposed that the life table should be accommodated to the HBV prognosis progression model so that it can more properly explain the disease progression of the HBV patients. But in the literature, no further disease analysis and applications of it with the life table are discussed. In this thesis, we assume that the original disease progression is described by a Markov model, and propose a new method to combine the HBV progression with the life table so that the proposed model integrates data from the life table and allows the accommodation of age-dependent properties of the target disease. With clinical data based on annual incidence rates, the entire model is Semi-Markov based in nature. Computation methods similar to the celebrated Chapman-Kolmogorov equation can be applied to study the associated probability of each likely trajectory with desired initial ages and health states under the scenarios of natural history and various treatment policies. This method provides a more accurate way to analyze the transitions between symptoms, such as the mean life expectancy or the survival probabilities at different ages. We will give examples to demonstrate the proposed method in this thesis. Numerical results show the proposed model not only provides a more accurate method to analyze the mean life expectancy, the survival probabilities at different ages, and the transition probabilities from symptoms to death but also helps us to understand the transitions between symptoms.
參考文獻: 1. Anderson, P.K., Multistate models in survival analysis: A study of nephropathy and mortality in diabetes. Statistics in Medicine 7, pp. 661-670, 1988.
2. Bambha, K., and Kim, W.R., Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls. European journal of gastroenterology and hepatology, vol. 16, no. 4, 2006.
3. Barbu, Vlad Stefan, Limnios, Nikolaos, Semi-Markov Chains and Hidden Semi-Markov Models toward Applications. Springer: New York, 2008.
4. Beck J.R, Pauker, S.G., The Markov process in medical prognosis. Medical Decision Making.1983; 3: 419-58.
5. Biase, G.D., D’Amico, G. Girolamo, A.D. Janssen, J. etc., A stochastic model for the HIV/AIDS dynamic evolution. Mathematical Problems in Engineering, pp. 1-14, 2007.
6. Bortolotti, F., Jara, P., Crivellaro, C., Hierro, L., Cadrobbi, P., Frauca, E., Camarena, C., De La Vega, A., Diaz, C., De Moliner L., and Noventa, F., Outcome of chronic hepatitis B in Caucasian children during a 20-year observation period. J. Hepatol. vol. 29, pp. 184-190, 1998.
7. Chu, C.J., Hussain , M., and Lok, A.S.F., Hepatitis B virus genotype B is associated with earlier HBeAg seroconversion compared to hepatitis B virus genotype C. Gastroenterology, vol. 122, pp. 1756-1762, 2002.
8. Chu, C.M., and Liaw, Y.F., Genotype C hepatitis B virus infection is associated with a higher risk of reactivation of hepatitis B and progression to cirrhosis than genotype B: A longitudinal study of hepatitis B e antigen-positive patients with normal aminotransferase levels at baseline. Journal of Hepatology, vol. 43, pp. 411-417, 2005.
9. Chu, C.M., Hung, S.J., Lin, J., Tai, D.I., and Liaw, Y.F., Natural history of hepatitis B e antigen to antibody seroconversion in patients with normal serum aminotransferase Levels. The American Journal of Medicine, vol. 116, pp. 829-834, 2004.
10. Cinlar, E., Introduction to Stochastic Processes. Prentice Hall: Englewood Cliffs, New Jersey, 1975.
11. Fattovich, G., Natural history and prognosis of hepatitis B. Seminar in Liver Disease, vol. 23, pp. 47-58, 2003.
12. Fattovich, G., Rugge, M., Brollo, L., Pontisso, P,. Noventa, F., Guido, M., Alberti, A., and Realdi, G., Clinical, virologic and histologic outcome following seroconversion from HBeAg to anti-HBe in chronic hepatitis type B. Hepatology, vol. 6, pp. 167-172, 1986.
13. Gambarin-Gelwan, M,. and Jacobson, I., Treatment of chronic hepatitis B infection,2007.www.gastro.org/.../Documents/08_Publications/06_GIHep_Annual_Review/Articles/GambarinGelwan-Jacobson.pdf.
14. Garber, A.M., Phelps, C.E., Economic foundations of cost-effectiveness analysis. Journal of Health Economics, vol. 17, pp. 1-31, 1997.
15. Hsu, Y.S., Chien, R.N., Yeh, C.T., Sheen, I.S., Chiou, H.Y., Chu, C.M., and Liaw, Y.F., Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology, vol. 35, pp. 1522-1527, 2002.
16. Kay, R., A Markov model for analyzing cancer marker and disease states and survival studies. Biometrics 42, pp. 855-865, 1986.
17. Lefebvre, M. Applied Stochastic Process. Springer: New York, 2006.
18. Luh, P.H., and Phua, S. A cost-effective analysis for chronic Hepatitis B Virus with cirrhosis by discrete event simulation. ISPR Asia-Pacific Conference, pp. 64-65, Seoul, South Korea, 2008.
19. Liaw, Y.F., and Chu, C.M., “Hepatitis B virus Infection,” The Lancet, pp. 582-592, Feb., 2009.
20. Liaw, Y.F., Hepatitis B virus replication and liver and disease progression: the impact of antiviral therapy. Antiviral Theory, vol. 11, pp. 669-679, 2006.
21. Minitab , version 15, Minitab, Inc., University Park, USA, 2007.
22. Orito, E., Mizokami, M., Sakugawa, H., Michitaka, K., Ishikawa, K., Ichida, T., Okanoue, T., Yotsuyanagi, H., and Iino, S., A case-control study for clinical and molecular biological diffferences between hepatitis B viruses of genotype B and C. Japan HBV Genotype Research Group. Hepatology, vol. 33, pp. 218-223, 2001.
23. Pwu, R.F., and Chan, K.A., Cost-effectiveness analysis of interferon-alpha therapy in the treatment of chronic hepatitis B in Taiwan. J. Formosa Med. Assoc., vol. 11, pp. 632-41, 2002.
24. Ross, S.M., Introduction to probability models. Academic Press, M.A., 2003.
25. Russell, L.B., Gold, M.R., Siegel, J. E. Daniels, N. and Weinstein, M. C. The role of cost-effectiveness analysis in health and medicine. JAMA., vol. 276, no. 14, pp. 1172-1177, 1996.
26. Satten, G. A. and Sternberg, M.R., Fitting Semi-Markov models to interval-censored data with unknown initiation times. Biometrics, vol. 55, no. 2, pp. 507-513, 1999.
27. Sonnenberg, F.A., Beck J.R., Markov models in medical decision making: a practical guide. Medical Decision Making 1993, 13(4),pp. 322-38.
28. Sternberg, M.R., De Angelis, D., and Aalen, O.O., Bayesian back-calculation using a multi-state model with application to HIV. Statistics in Medicine, vol. 24, no. 24, pp. 3991-4007, 2005.
29. Taha, H.A., Operations Reaseach an introduction. Eighth edition, Pearson Edutacion, Inc.. 2003.
30. 行政院內政部統處,第九次(民國88~90年)臺灣地區國民生命表http://www.moi.gov.tw/stat/life.aspx
31. 行政院內政部統計處,簡易生命表函數定義及編算方法 http://www.moi.gov.tw/stat/life.aspx
描述: 碩士
國立政治大學
應用數學研究所
97751001
99
資料來源: http://thesis.lib.nccu.edu.tw/record/#G0097751001
資料類型: thesis
Appears in Collections:學位論文

Files in This Item:
File SizeFormat
100101.pdf5.09 MBAdobe PDF2View/Open
Show full item record

Google ScholarTM

Check


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.